Expression of Components of the Renin-Angiotensin System by the Putative Stem Cell Population Within WHO Grade I Meningioma

Shivapathasundram, Ganeshwaran; Wickremesekera, Agadha; Brasch, Helen D.; Schaijik, Bede van; Marsh, Reginald; Tan, Swee T.; Itinteang, Tinte

doi:10.3389/fsurg.2019.00023

Cited by 6 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…151 Cells in numerous cancer types, including brain tumors such as GBM, have been found to express both CSC markers and components of the RAS. 152 In two similar studies, Shivapathasundram et al 150 reported the expression of PRR, ACE, ATIIR1, and ATIIR2 and Rahman et al 153 reported the expression of cathepsin B, cathepsin D, and, to a lesser extent, cathepsin G in a putative stem cell population of low-grade meningioma. Given that the RAS is overexpressed in a wide range of tumors, numerous studies have assessed the effect of RAS inhibitors in vitro and on tumor models in vivo.…”

Section: Antihypertensive Drugsmentioning

confidence: 96%

“…ATIIR1 induces angiogenesis and cellular proliferation. 150 Prorenin, through its receptor pattern recognition receptor (PRR), is another important component of the RAS implicated in carcinogenesis through its involvement in the Wnt/β-catenin signaling pathway. 151 Cells in numerous cancer types, including brain tumors such as GBM, have been found to express both CSC markers and components of the RAS.…”

Section: Antihypertensive Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Repurposing of Anticancer Stem Cell Drugs in Brain Tumors

Bahmad

Daher

Aljamal

et al. 2021

J Histochem Cytochem.

View full text Add to dashboard Cite

Brain tumors in adults may be infrequent when compared with other cancer etiologies, but they remain one of the deadliest with bleak survival rates. Current treatment modalities encompass surgical resection, chemotherapy, and radiotherapy. However, increasing resistance rates are being witnessed, and this has been attributed, in part, to cancer stem cells (CSCs). CSCs are a subpopulation of cancer cells that reside within the tumor bulk and have the capacity for self-renewal and can differentiate and proliferate into multiple cell lineages. Studying those CSCs enables an increasing understanding of carcinogenesis, and targeting CSCs may overcome existing treatment resistance. One approach to weaponize new drugs is to target these CSCs through drug repurposing which entails using drugs, which are Food and Drug Administration–approved and safe for one defined disease, for a new indication. This approach serves to save both time and money that would otherwise be spent in designing a totally new therapy. In this review, we will illustrate drug repurposing strategies that have been used in brain tumors and then further elaborate on how these approaches, specifically those that target the resident CSCs, can help take the field of drug repurposing to a new level.

show abstract

Section: Antihypertensive Drugsmentioning

confidence: 96%

Section: Antihypertensive Drugsmentioning

confidence: 99%

Repurposing of Anticancer Stem Cell Drugs in Brain Tumors

Bahmad

Daher

Aljamal

et al. 2021

J Histochem Cytochem.

View full text Add to dashboard Cite

show abstract

“…Angiotensin II (ATII), which binds to the ATII type 1 receptor (ATIIR1) and ATIIR2, is the main effector of the renin–angiotensin system (RAS). ATIIR1 induces angiogenesis and cell proliferation [ 45 ]. Prorenin is also an important component of the RAS implicated in carcinogenesis through the Wnt/β-catenin signaling pathway [ 46 ].…”

Section: Meningiomamentioning

confidence: 99%

“…Prorenin is also an important component of the RAS implicated in carcinogenesis through the Wnt/β-catenin signaling pathway [ 46 ]. The prorenin receptor, angiotensin converting enzyme, ATIIR1, and ATIIR2, which are components of the RAS, were expressed on the stem cell population in meningiomas, suggesting that these stem cells may be a potential therapeutic target through the inhibition of the RAS [ 45 , 47 ]. β-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers reduced tumor cell growth in various types of cancer, suggesting a potential utility of the repositioning of these drugs for the treatment of meningioma [ 48 ].…”

Section: Meningiomamentioning

confidence: 99%

Drug Repositioning for Refractory Benign Tumors of the Central Nervous System

Tamura

2023

IJMS

View full text Add to dashboard Cite

Drug repositioning (DR) is the process of identifying novel therapeutic potentials for already-approved drugs and discovering new therapies for untreated diseases. DR can play an important role in optimizing the pre-clinical process of developing novel drugs by saving time and cost compared with the process of de novo drug discovery. Although the number of publications related to DR has rapidly increased, most therapeutic approaches were reported for malignant tumors. Surgical resection represents the definitive treatment for benign tumors of the central nervous system (BTCNS). However, treatment options remain limited for surgery-, chemotherapy- and radiation-refractory BTCNS, as well as malignant tumors. Meningioma, pituitary neuroendocrine tumor (PitNET), and schwannoma are the most common BTCNS. The treatment strategy using DR may be applied for refractory BTCNS, such as Grade 2 meningiomas, neurofibromatosis type 2-related schwannomatosis, and PitNETs with cavernous sinus invasion. In the setting of BTCNS, stable disease can provide significant benefit to the patient. DR may provide a longer duration of survival without disease progression for patients with refractory BTCNS. This article reviews the utility of DR for refractory BTCNS.

show abstract